These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36282797)

  • 1. Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis.
    Moiseev I; Tcvetkov N; Epifanovskaya O; Babenko E; Parfenenkova A; Bakin E; Yurovskaya K; Morozova E
    PLoS One; 2022; 17(10):e0275399. PubMed ID: 36282797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8
    Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
    J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.
    Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.
    Cheng P; Eksioglu EA; Chen X; Kandell W; Le Trinh T; Cen L; Qi J; Sallman DA; Zhang Y; Tu N; Adams WA; Zhang C; Liu J; Cleveland JL; List AF; Wei S
    Leukemia; 2019 Aug; 33(8):2034-2046. PubMed ID: 30737486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
    Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
    Front Immunol; 2022; 13():950134. PubMed ID: 36003379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
    Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
    Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative Analysis on Immunophenotype of CD34
    Chen X; Ren FG; Zhang YF; Xu J; Xia T; Chang JM; Chen XH; Tan YH; Wang HW; Xu ZF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):832-839. PubMed ID: 34105480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
    Pribyl M; Hubackova S; Moudra A; Vancurova M; Polackova H; Stopka T; Jonasova A; Bokorova R; Fuchs O; Stritesky J; Salovska B; Bartek J; Hodny Z
    Mol Oncol; 2020 Oct; 14(10):2403-2419. PubMed ID: 32696549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
    Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome.
    Fu R; Li L; Hu J; Wang Y; Tao J; Liu H; Liu Z; Zhang W
    J Investig Med; 2019 Dec; 67(8):1125-1130. PubMed ID: 31511310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
    Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
    Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features.
    Porwit A; Rajab A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():133-43. PubMed ID: 25976971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.